NewLink, GSK get U.S. funding for faster development of Ebola vaccines

Dec 23 (Reuters) - The U.S. Department of Health and Human Services (HHS) awarded contracts worth a total of about $43 million to NewLink Genetics Corp and GlaxoSmithKline Plc for faster development of two Ebola vaccines.